The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2026)
Availability
On-Demand
Expires on May 26, 2027
Cost
$0.00
Credit Offered
3.75 AMA PRA Category 1 Credit Credits
3.75 Participation Credits
The Evolving Landscape of Advanced Prostate Cancer Treatment is a complimentary, comprehensive, guidelines-driven and case-based program designed to equip clinicians with up-to-date strategies for managing complex disease states across the prostate cancer continuum. Faculty will explore multidisciplinary care models, genetic testing, next-generation imaging and theranostics. Case-based discussions will provide practical guidance on treatment selection and sequencing for hormone-sensitive and castration-resistant prostate cancer—including M0 and M1 disease—as well as precision medicine and emerging therapeutic options. Participants will leave with actionable insights to optimize individualized care in an increasingly sophisticated therapeutic landscape.

ACKNOWLEDGEMENTS: 
Support provided by independent educational grants from:
Astellas, AstraZeneca, Blue Earth Diagnostics, Inc., Lantheus Medical Imaging, Merck & Co. Inc., Novartis Pharmaceuticals Corporation and Pfizer, Inc. 
  • Urologists 
  • Residents
  • APPs
At the conclusion of this activity, participants will be able to: 

PRACTICE GAP #1 (DISEASE STATE)1. Recognize the natural progression of advanced prostate cancer (APC) from biochemical recurrence (BCR) after local therapy to metastatic hormone-sensitive (M1HSPC) and castration-resistant disease (M0CRPC and M1CRPC).
2. Describe risk and volume stratification, treatment approaches, therapeutic goals, and outcomes for newly diagnosed M1HSPC, including intensification strategies with double or triple therapy (novel hormonal agents and/or chemotherapy).
3. Discuss the role of germline and somatic genetic testing in managing men with high-risk, metastatic prostate cancer and castration-resistant prostate cancer (CRPC) and its implications for treatment.

PRACTICE GAP #2 (GUIDELINES)
4. Provide treatment recommendations for APC based on the AUA/SUO Advanced Prostate Cancer Guidelines.
5. Counsel patients on management strategies for M1HSPC including treatment intensification and deintensification, and sequencing of agents for M1CRPC based on clinical presentation and prior treatment.

PRACTICE GAP #3 (ANDROGEN AXIS)
6. Evaluate the clinical efficacy and optimal use of approved androgen-axis therapeutics both as monotherapy and in combination for the management of APC.
7. Anticipate and manage adverse events arising from androgen-axis targeted agents used in the treatment of APC to optimize outcomes and patient quality of life.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND THERANOSTICS and COMORBIDITIES)
8. Describe the AUA/SUO guideline-based indications and sequencing for chemotherapy, immunotherapy, PARP Inhibitors and theranostic agents in the management of patients with APC.
9. Identify germline and somatic mutations relevant to M1CRPC and discuss their therapeutic implications including indications for PARP Inhibitor use.

PRACTICE GAP #5 (BONE HEALTH, MANAGING PAIN AND RADIONUCLIDE THERAPY)
10. Integrate advances in bone health management into patient-specific care plans among men with APC.
11. Assess and manage pain in patients with symptomatic M1HSPC and M1CRPC and discuss the role of palliative care and supportive services in the management of late stage M1CRPC.
12. Recommend and prescribe radionuclide therapy in appropriate patients with M1CRPC.

PRACTICE GAP #6 (DEVELOPING AN ADVANCED PROSTATE CANCER CLINIC)
13. Develop a framework for establishing and operationalizing a multidisciplinary prostate cancer clinic. 
FACULTY DISCLOSURES 
Name Company Name Relationship Type End Date
Barata, Pedro Exelixis Consultant or Advisor Current
Caris Life Sciences Consultant or Advisor Current
Pfizer Consultant or Advisor Current
Seattle Genetics Scientific Study or Trial Current
Bayer Consultant or Advisor Current
Novartis Consultant or Advisor Current
Astra Zeneca Consultant or Advisor Current
Ipsen Consultant or Advisor Current
Eisai Meeting Participant or Lecturer Current
Boorjian, Stephen A. Ferring Consultant or Advisor  
Johnson & Johnson Consultant or Advisor  
Cookson, Michael S. No relevant financial relationships to disclose
Dunn, Mary W. No relevant financial relationships to disclose
Gomella, Leonard G. Merck Pharmaceuticals Consultant or Advisor Current
Astra Zeneca Consultant or Advisor Current
Lantheus Consultant or Advisor Current
Blue Earth Consultant or Advisor Current
Jarrad, David No relevant financial relationships to disclose
Morgans, Alicia Bayer Consultant or Advisor Current
Astra Zeneca Consultant or Advisor Current
Astellas Consultant or Advisor Current
Dendreon Consultant or Advisor Current
Merck Pharmaceuticals Consultant or Advisor Current
BMS Consultant or Advisor Current
Pfizer Consultant or Advisor Current
Advanced Accelerator Applications Consultant or Advisor Current
Lantheus Consultant or Advisor Current
Myriad Consultant or Advisor Current
Telix Consultant or Advisor Current
Novartis  Consultant or Advisor Current
Macrogenics Consultant or Advisor Current
Tolmar Consultant or Advisor Current
Eli Lilly Consultant or Advisor Current
LOXO@Lilly Consultant or Advisor Current
Sumitomo Pharma Consultant or Advisor Current
Celex Consultant or Advisor Current
GSK Consultant or Advisor Current
Exact Sciences Consultant or Advisor Current
Johnson & Johnson Consultant or Advisor Current
Moses, Kelvin A. No relevant financial relationships to disclose
Scarpato, Kristen R. No relevant financial relationships to disclose
Stratton, Kelly L. No relevant financial relationships to disclose


EDUCATION COUNCIL DISCLOSURES
Education Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2026
Expiration Date: May, 2027

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 3.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.